Related Experiment Video
Updated: Aug 19, 2026
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Effect of atorvastatin upon platelet activation in hypercholesterolemia, evaluated by flow cytometry
Manuel Labiós1, Marcial Martínez, Francisco Gabriel
1Department of Internal Medicine, Clinic University Hospital, Valencia, Spain.
Insights
Hyperlipidemia increases cardiovascular risk by causing platelet hyperactivation. Atorvastatin therapy normalized platelet function and correlated with reduced cholesterol levels in hypercholesterolemic patients.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Pharmacology
Background:
- Hyperlipidemia is a known cardiovascular disease risk factor.
- Platelet activation significantly contributes to atherothrombotic events.
- Limited research exists on platelet activation in hypercholesterolemia and the effects of lipid-lowering drugs.
Purpose of the Study:
- To assess in vivo and in vitro platelet activation in hypercholesterolemic patients.
- To evaluate the ex vivo effect of atorvastatin on platelet activation.
- To determine if changes in platelet function correlate with plasma lipid normalization.
Main Methods:
- Whole blood flow cytometry was used to measure platelet activation markers (GPIIb/IIIa, phosphatidylserine, CD62).
- A cohort of 33 hypercholesterolemic patients and 40 normolipidemic controls was studied.
- Patients received 20 mg/day of atorvastatin, and its ex vivo effects were assessed.
Main Results:
- Hypercholesterolemic patients exhibited significantly higher percentages of GPIIb/IIIa- and phosphatidylserine-positive platelets in vivo compared to controls.
- In vitro platelet response (CD62 expression to thrombin) was greater in patients.
- Atorvastatin therapy normalized platelet hyperfunction and reduced GPIIb/IIIa response to ADP, correlating with decreased total and LDL cholesterol.
Conclusions:
- Hypercholesterolemia is associated with in vivo and in vitro platelet hyperactivation.
- Atorvastatin effectively normalizes platelet hyperfunction in hypercholesterolemic patients.
- The normalization of platelet function is significantly correlated with the reduction of plasma lipid levels.
Abstract:
Hyperlipidemia is a well established risk factor for cardiovascular disease and atherothrombotic events, in which platelet activation also plays a significant role. However, very few studies have addressed platelet activation in hypercholesterolemia, the potential effect of lipid lowering drugs upon platelet hyperfunction, and the question of whether changes in the latter are correlated to normalization of plasma lipids. This study used whole blood flow cytometry to assess in vivo and in vitro platelet activation in a group of 33 patients with hypercholesterolemia, and also the ex vivo effect of atorvastatin (20 mg/day) upon such activation. A control group of 40 normolipidemic volunteers matched in terms of age, sex and added risk factors to the patient group was used. The results showed that hypercholesterolemic patients had in vivo a significantly greater percentage of GPIIb/IIIa- and phosphatidylserine-positive platelets compared with the control group (4.62+/-3.51% and 2.58+/-1.19% versus 2.73+/-1.08% and 1.54+/-0.68%, respectively). In vitro response of CD62 expression to thrombin was also greater in the patients than in the controls (92.51+/-6.00% versus 89.63+/-10.72%, p<0.05). Atorvastatin therapy normalized platelet hyperfunction in the patients studied and reduced GPIIb/IIIa response to ADP (from 82.65+/-6.43% to 75.84+/-4.89%, p<0.01). A significant correlation can be seen between such normalization and the decrease in plasma levels of total and LDL cholesterol.
